Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.
Advanced Malignancies
DRUG: MGCD265
To assess the bioavailability of two MGCD265 formulations., To compare the rate and extent of absorption of two MGCD265 oral formulations at dose level of 100 mg administered as 1 x 100 mg oral dose (Formulation A) and 2 x 50 mg oral dose (Formulation B) under fasting conditions., Two months
The objective of this study is to compare the rate and extent of absorption of two MGCD265 oral formulations at a dose level of 100 mg administered to healthy male and female subjects under fasting conditions.